Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Onychomycosis
Interventions: Terbinafine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Liver MultiScan; Device
Lead sponsor: Perspectum; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training
Interventions: Fundamental Adaptive Skills Training, Relaxation and Mindfulness Training; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Fatty Liver
Interventions: High fat meal, Morphine; Other · Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: clarithromycin 500mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
Interventions: Access to Cue Health COVID-19 Remote testing and treatment for COVID-19; Other
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 2,117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Healthy Participants
Interventions: AZD8965, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: .[14C]-SKI-O-703; Drug
Lead sponsor: Oscotec Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Lung Injury
Interventions: Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis; Drug · Other · Procedure
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Clackamas, Oregon • Portland, Oregon

Conditions: Major Depressive Disorder, Alcohol Use Disorder
Interventions: Ketamine + Naltrexone, Ketamine + Placebo, Placebo (psychoactive placebo midazolam) + Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Drug Pharmacokinetics in Healthy Volunteers
Interventions: DS-8500a, Rosuvastatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer, Prostate Cancer Metastatic
Interventions: Fasting, Ketone Supplementation; Behavioral · Dietary Supplement
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-788, Itraconazole, Rifampin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Craniofacial Surgery
Interventions: High Dissolving Transitional Food; Dietary Supplement
Lead sponsor: NYU Langone Health; Other
Eligibility: 6 Months to 18 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Pharmacokinetics
Interventions: 250 mg encapsulated caffeine; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Sleep, Consolidation
Interventions: Targeted memory reactivation (sounds); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dentin Sensitivity
Interventions: Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate); Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Erosive Esophagitis
Interventions: Esophageal Barium Xray; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Diabetes Mellitus, Type 2, Pre Diabetes
Interventions: Parkland Diabetes Detection Program (PDDP) Screening Invitation; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Lymphoma
Interventions: rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 153
States / cities: Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more

Conditions: Healthy Volunteers
Interventions: ASP1617, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: LY4100511 (DC-853), [14C]-LY4100511 (DC-853) Administered oral dose, [14C]-LY4100511 (DC-853); Drug
Lead sponsor: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Intubation; Difficult
Interventions: Miller blade, Truview PCD, Glidescope Cobolt; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions

Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population

The Fundamental Adaptive Skills Training

Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease

Bioequivalence Study of Clarithromycin 500 mg Tablets Under Non-Fasting Conditions

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants

A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

Effect of Repeated Doses of DS-8500a on Pharmacokinetics of Rosuvastatin in Healthy Volunteers

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

A Study to Evaluate Drug-Drug Interaction of TAK-788 With Itraconazole and Rifampin in Healthy Adult Participants

Effect of Novel High Dissolving Transitional Foods

Pilot Study Characterizing the Pharmacokinetic Profile of a Novel Encapsulated Caffeine Beverage in the Fed and Fasted States

Reinstatement of Context During Sleep and Its Subsequent Effect on Memory: an fMRI Study

To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

A Relative Bioavailability Study of 60 mg Nifedipine ER Tablets Under Non-fasting Conditions

Increasing Uptake of EHR-enabled Population Health Outreach Strategies to Improve Diabetes Screening

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect

A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants

A Comparison Between Two Video Laryngoscopes,in Successfully Intubating Pediatric Mannequins w/wo Difficult Airways